Related Experiment Video

Updated: Mar 7, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.8K

MiR-30 Family Potentially Targeting PI3K-SIAH2 Predicted Interaction Network Represents a Novel Putative Theranostic

Lawrence W C Chan1, Fengfeng Wang1, Fei Meng1

  • 1Department of Health Technology and Informatics, Hong Kong Polytechnic University Hong Kong, Hong Kong.

Frontiers in Genetics
|February 18, 2017
PubMed

Insights

This study investigates phosphoinositide-3-kinase (PI3K) and seven in absentia homolog 2 (SIAH2) in non-small cell lung cancer (NSCLC). Findings suggest PI3K and SIAH2 may be co-targets to overcome drug resistance in NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Non-small cell lung cancer (NSCLC) has a low survival rate due to drug resistance.
  • Phosphoinositide-3-kinase (PI3K) influences sensitivity to tyrosine kinase inhibitors (TKIs).
  • Seven in absentia homolog 2 (SIAH2) is upregulated in NSCLC and linked to tumor grade.

Purpose of the Study:

  • To clarify the relationship between PI3K and SIAH2 in NSCLC.
  • To investigate their potential as co-targets for overcoming TKI resistance.
  • To explore their role as theranostic dual markers.

Main Methods:

  • Bioinformatics analyses utilizing mass spectrometry data.
  • Exploration of indirect interaction between PI3K and SIAH2.
  • Prediction of common targeting microRNAs, including the miR-30 family.

Main Results:

  • Upregulated SIAH2 expression was confirmed in NSCLC.
  • An indirect interaction between PI3K and SIAH2 was identified.
  • The potential regulatory role of the miR-30 family in the PI3K-SIAH2 interaction was explored.

Conclusions:

  • PI3K and SIAH2 are potential co-targets for NSCLC treatment.
  • The miR-30 family may modulate the PI3K-SIAH2 interaction, offering therapeutic avenues.
  • Further research into PI3K, SIAH2, and miR-30 could lead to novel strategies against TKI resistance in NSCLC.
Keywords:
PI3KSIAH2microRNAnon-small cell lung cancertheranostics

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.6K